MicroRNA controlled adenovirus mediates anti-cancer efficacy without affecting endogenous microRNA activity

PLoS ONE

Volumn 6, Issue 1, 2011, Pages

  Cawood, Ryan ^a   Wong, Suet Ling ^a   Di, Ying ^a   Baban, Dilair F ^b   Seymour, Leonard W ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; MICRORNA; MICRORNA 122; MICRORNA 21; UNCLASSIFIED DRUG; MIRN22 MICRORNA, HUMAN;

ADENOVIRUS 5; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CELL STRAIN HEPG2; CONTROLLED STUDY; DOWN REGULATION; DRUG DOSE ESCALATION; DRUG EFFICACY; FEMALE; GENE TARGETING; GENETIC ASSOCIATION; GENETIC TRANSCRIPTION; HEPATITIS; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHARMACODYNAMICS; PROTEIN DEPLETION; PROTEIN FUNCTION; PROTEIN STRUCTURE; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIROTHERAPY; VIRUS PARTICLE; VIRUS REPLICATION; WESTERN BLOTTING; ADENOVIRUS; ANIMAL; CHEMISTRY; EXPERIMENTAL NEOPLASM; GENETICS; LIVER; TREATMENT OUTCOME; VIRION; XENOGRAFT;

ADENOVIRIDAE; HUMAN ADENOVIRUS TYPE 5; MUS;

ADENOVIRIDAE; ANIMALS; HEP G2 CELLS; HUMANS; LIVER; MICE; MICRORNAS; NEOPLASMS, EXPERIMENTAL; TRANSPLANTATION, HETEROLOGOUS; TREATMENT OUTCOME; VIRION;

EID: 79251559669     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0016152     Document Type: Article

References (35)

1. Lun XQ, Yang WQ, Alain T, Shi ZQ, Muzik H, et al. (2005) Myxoma virus is a novel oncolytic virus with significant antitumor activity against experimental human gliomas. Cancer Research 65(21): 9982-9990.
2. Stojdl DF, Lichty BD, tenOever BR, Paterson JM, Power AT, et al. (2003) VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 4(4): 263-275.
3. Msaouel P, Lankov LD, Allen C, Morrs JC, von Messling V, et al. (2009) Engineered Measles Virus as a Novel Oncolytic Therapy Against Prostate Cancer. Prostate 69(1): 82-91.
4. Kelly EJ, Russell SJ (2009) MicroRNAs and the Regulation of Vector Tropism. Molecular Therapy 17(3): 409-416.
5. Barnes D, Kunitomi M, Vignuzzi M, Saksela K, Andino R (2008) Harnessing endogenous miRNAs to control virus tissue tropism as a strategy for developing attenuated virus vaccines. Cell Host & Microbe 4(3): 239-248.
6. Schaefer A, K Jung Re: Micro RNA Regulation of Oncolytic Herpes Simplex Virus-1 for Selective Killing of Prostate Cancer Cells. European Urology 57(5): 919-919.
7. Kelly EJ, Nace R, Barber GN, Russell SJ. Attenuation of Vesicular Stomatitis Virus Encephalitis through MicroRNA Targeting. Journal of Virology 84(3): 1550-1562.
8. Edge RE, Falls TJ, Brown CW, Lichty BD, Atkins H, et al. (2008) A let-7 microRNA-sensitive vesicular stomatitis virus demonstrates tumor-specific replication. Molecular Therapy 16(8): 1437-1443.
9. Perez JT, Pham AM, Lorini MH, Chua MA, Steel J, et al. (2009) MicroRNAmediated species-specific attenuation of influenza A virus. Nature Biotechnology 27(6): 572-U117.
10. Cawood R, Chen HH, Carroll F, Bazan-Peregrino M, van Rooijen N, et al. (2009) Use of Tissue-Specific MicroRNA to Control Pathology of Wild-Type Adenovirus without Attenuation of Its Ability to Kill Cancer Cells. Plos Pathogens 5(5).
11. Ylosmaki E, Hakkarainen T, Hemminki A, Visakorpi T, Andino R, et al. (2008) Generation of a Conditionally Replicating Adenovirus Based on Targeted Destruction of E1A mRNA by a Cell Type-Specific MicroRNA. Journal of Virology 82(22): 11009-11015.
12. Lee TC, Lin YL, Liao JT, Su CM, Lin CC, et al. Utilizing liver-specific microRNA-122 to modulate replication of dengue virus replicon. Biochemical and Biophysical Research Communications 396(3): 596-601.
13. Kamrud KI, McNeil Coffield V, Owens G, Goodman C, Alterson K, et al. (2010) In-vitro and In-vivo Characterization of MicroRNA Targeted Alphavirus Replicon and Helper RNAs. Journal of Virology Published online ahead of print.
14. Brown BD, Venneri MA, Zingale A, Sergi LS, Naldini L (2006) Endogenous microRNA regulation suppresses transgene expression in hematopoietic lineages and enables stable gene transfer. Nature Medicine 12(5): 585-591.
15. Suzuki T, Sakurai F, Nakamura SI, Kouyama E, Kawabata K, et al. (2008) miR-122a-regulated expression of a suicide gene prevents hepatotoxicity without altering antitumor effects in suicide gene therapy. Molecular Therapy 16 (10): 1719-1726.
16. Lichtenstein DL, Wold WS (2004) Experimental infections of humans with wildtype adenoviruses and with replication-competent adenovirus vectors: replication, safety, and transmission. Cancer Gene Ther 11(12): 819-29.
17. Duncan SJ, Gordon FCA, Gregory DW, McPhie JL, Postlethwaite R, et al. (1978) Infection of Mouse-Liver by Human Adenovirus Type-5. Journal of General Virology 40 (JUL): 45-61.
18. Engler H, Machemer T, Philopena J, Wen SF, Quijano E, et al. (2004) Acute hepatotoxicity of oncolytic adenoviruses in mouse models is associated with expression of wild-type E1a and induction of TNF-alpha. Virology 328(1): 52-61.
19. Majem M, Cascallo M, Bayo-Puxan N, Mesia R, Germa JR, et al. (2006) Control of E1A under an E2F-1 promoter insulated with the myotonic dystrophy locus insulator reduces the toxicity of oncolytic adenovirus Ad- Delta24RGD. Cancer Gene Ther 13(7): 696-705.
20. Gentner B, Schira G, Giustacchini A, Amendola M, Brown BD, et al. (2009) Stable knockdown of microRNA in vivo by lentiviral vectors. Nature Methods 6(1): 63-66.
21. Brown BD, Gentner B, Cantore A, Colleoni S, Amendola M, et al. (2007) Endogenous microRNA can be broadly exploited to regulate transgene expression according to tissue, lineage and differentiation state. Nature Biotechnology 25(12): 1457-1467.
22. Mittereder N, March KL, Trapnell BC (1996) Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J Virol 70(11): 7498-509.
23. Karber G (1931) 50% end-point calculation. Arch. Exp. Pathol. Pharmak 162: 480-483.
24. Tomayko MM, Reynolds CP (1989) Determination of Subcutaneous Tumor Size in Athymic (Nude) Mice. Cancer Chemotherapy and Pharmacology 24(3):148-154.
25. Pfaffl MW (2001) A new mathematical model for relative quantification in realtime RT-PCR. Nucleic Acids Research 29(9).
26. Edgar R, Domrachev M, Lash AE (2002) Gene Expression Omnibus: NCBIgene expression and hybridization array data repository. Nucleic Acids Research 30(1): 207-210.
27. Chang J, Nicolas E, Marks D, Sander C, Lerro A, et al. (2004) miR-122, a mammalian liver-specific micro RNA, is processed from hcr mRNA and may down regulate the high affinity cationic amino acid transporter CAT-1. RNA Biol 1(2): 106-113.
28. Coulouarn C, Factor VM, Andersen JB, Durkin ME, Thorgeirsson SS (2009) Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene 28(40): 3526-3536.
29. Bazan-Peregrino M, Carlisle RC, Hernandez-Alcoceba R, Iggo R, Homicsko K, et al. (2008) Comparison of molecular strategies for breast cancer virotherapy using oncolytic adenovirus. Human Gene Therapy 19(9): 873-886.
30. Mathonnet G, Fabian MR, Svitkin YV, Parsyan A, L Huck, et al. (2007) MicroRNA inhibition of translation initiation in vitro by targeting the capbinding complex elF4F. Science 317(5845): 1764-1767.
31. Esau C, Davis S, Murray SF, Yu XX, Pandey SK, et al. (2006) miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metabolism 3(2): 87-98.
32. Fabani MM, Gait MJ (2008) miR-122 targeting with LNA/2 9-O-methyl oligonucleotide mixmers, peptide nucleic acids (PNA), and PNA-peptide conjugates. Rna-a Publication of the Rna Society 14(2): 336-346.
33. Kelly EJ, Hadac EM, Greiner S, Russell SJ (2008) Engineering microRNA responsiveness to decrease virus pathogenicity. Nature Medicine 14(11): 1278-1283.
34. Perez JT, Pham AM, Lorini MH, Chua MA, Steel J, et al. (2009) MicroRNAmediated species-specific attenuation of influenza A virus. Nat Biotech 27(6): 572-576.
35. Grimm D, Streetz KL, Jopling CL, Storm TA, Pandey K, et al. (2006) Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 441(7092): 537-541.